Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro.

Wadhwa, R; Paudel, KR; Chin, LH; Hon, CM; Madheswaran, T; Gupta, G; Panneerselvam, J; Lakshmi, T; Singh, SK; Gulati, M; Dureja, H; Hsu, A; Mehta, M; Anand, K; Devkota, HP; Chellian, J; Chellappan, DK; Hansbro, PM; Dua, K

Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro.

Wadhwa, R Paudel, KR Chin, LH Hon, CM Madheswaran, T Gupta, G Panneerselvam, J Lakshmi, T Singh, SK Gulati, M Dureja, H Hsu, A Mehta, M Anand, K Devkota, HP Chellian, J Chellappan, DK Hansbro, PM Dua, K

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Journal of food biochemistry, 2020, pp. e13572
Issue Date:: 2020-11-29

Closed Access

	Filename	Description	Size
	Anti-inflammatory and anticancer activities......pdf	Published Version	1.95 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wadhwa, R
dc.contributor.author	Paudel, KR
dc.contributor.author	Chin, LH
dc.contributor.author	Hon, CM
dc.contributor.author	Madheswaran, T
dc.contributor.author	Gupta, G
dc.contributor.author	Panneerselvam, J
dc.contributor.author	Lakshmi, T
dc.contributor.author	Singh, SK
dc.contributor.author	Gulati, M
dc.contributor.author	Dureja, H
dc.contributor.author	Hsu, A
dc.contributor.author	Mehta, M
dc.contributor.author	Anand, K
dc.contributor.author	Devkota, HP
dc.contributor.author	Chellian, J
dc.contributor.author	Chellappan, DK
dc.contributor.author	Hansbro, PM
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2020-12-22T21:59:23Z
dc.date.available	2020-11-02
dc.date.available	2020-12-22T21:59:23Z
dc.date.issued	2020-11-29
dc.identifier.citation	Journal of food biochemistry, 2020, pp. e13572
dc.identifier.issn	0145-8884
dc.identifier.issn	1745-4514
dc.identifier.uri	http://hdl.handle.net/10453/144904
dc.description.abstract	In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. PRACTICAL APPLICATIONS: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Journal of food biochemistry
dc.relation.isbasedon	10.1111/jfbc.13572
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0908 Food Sciences
dc.subject.classification	Food Science
dc.title	Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro.
dc.type	Journal Article
utslib.location.activity	United States
utslib.for	0908 Food Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access	*
dc.date.updated	2020-12-22T21:59:13Z
pubs.publication-status	Published

Abstract:

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. PRACTICAL APPLICATIONS: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/144904